Last updated on April 19, 2014 at 21:20 EDT

ThromboGenics Lands Licensing Deal of the Year at SCRIP Awards 2012

November 29, 2012

LEUVEN, Belgium, November 29, 2012 /PRNewswire/ –

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company
focused on developing and commercializing innovative ophthalmic medicines, announces that
it won the Licensing Deal of the Year Award at the Scrip Awards 2012 event held in London
last night. The Company received the global industry recognition for its partnership
agreement with Alcon (Novartis) to commercialize JETREA(R) (ocriplasmin) outside the U.S.
JETREA(R) is the first pharmacological treatment for vitreomacular adhesion (VMA), a
progressive sight-threatening disease. JETREA(R) was recently approved by the U.S. Food
and Drugs Administration for the treatment of symptomatic Vitreomacular Adhesion (VMA).
The JETREA(R) European Marketing Authorisation Application is currently under review by
the European Medicines Agency. A decision on European approval is expected in the first
half of 2013.

The Scrip Awards, now in their eighth year, are one of the most prestigious awards
recognizing excellence in the global biopharmaceutical and clinical research industries.
The awards are judged by an independent panel of senior executives from these sectors
against strict criteria.

The Licensing Deal of the Year reflects the major partnership alliance that
ThromboGenics and Alcon signed for the commercialization of JETREA(R)in Europe and Rest of
the World (ROW). In the US, ThromboGenics will commercialize the drug by itself.

Upon the signing of the deal in March 2012, ThromboGenics received an upfront payment
of EUR75 million. ThromboGenics is eligible to receive up to a further EUR300 million in
potential milestone payments. ThromboGenics could also receive an attractive level of
royalties based on the net sales of JETREA(R)in the ROW, which would give it a significant
share of the product’s economics outside the U.S. In addition, ThromboGenics and Alcon
have agreed to work together and share the costs of developing new clinical applications
or presentations of JETREA(R).

Dr Patrik De Haes, CEO of ThromboGenics, said: “Winning this prestigious industry
award is a clear recognition of the strategic importance of this licensing deal for both
ThromboGenics and Alcon. As a result of this agreement, we now have the best possible
partner to commercialize JETREA(R)outside the U.S. With JETREA(R), Alcon has gained access
to a novel pharmacological treatment option that could lead to paradigm shift in the
treatment of symptomatic vitreomacular adhesion.”

About JETREA(R) (ocriplasmin)

JETREA(R) (ocriplasmin) is a truncated form of human plasmin for the treatment of
symptomatic VMA. JETREA(R)is a selective proteolytic enzyme that cleaves fibronectin,
laminin and collagen, three major components of the vitreoretinal interface that play an
important role in vitreomacular adhesion.

JETREA(R)has been evaluated in two multi-center, randomized, double-masked Phase III
trials conducted in the U.S. and Europe involving 652 patients with vitreomacular
adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.

JETREA(R)’s Phase III program found that 26.5% of patients treated with ocriplasmin
saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The
Phase III program also showed that JETREA(R) was generally well tolerated with most
adverse events being transient and mild in severity.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and
commercializing innovative ophthalmic medicines. The Company’s lead product,
JETREA(R)(ocriplasmin), has been approved by the FDA for the treatment of symptomatic VMA.
The Marketing Authorisation Application (MAA) for ocriplasmin is under review in Europe.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for
the commercialization of JETREA(R) outside the United States. Under this agreement,
ThromboGenics could receive up to a total of EUR375 million in up-front and milestone
payments. It will receive significant royalties from Alcon’s net sales of JETREA(R).
ThromboGenics and Alcon intend to share the costs equally of developing JETREA(R) for a
number of new vitreoretinal indications.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly
referred to as TB-403, for the treatment of ophthalmic indications.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (U.S)
and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under
the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such
forward-looking statements are based on current expectations, and, accordingly, entail and
are influenced by various risks and uncertainties. The Company therefore cannot provide
any assurance that such forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement, whether as a result of new
information, future events or any other reason. Additional information concerning risks
and uncertainties affecting the business and other factors that could cause actual results
to differ materially from any forward-looking statement is contained in the Company’s
Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase
of securities or assets of ThromboGenics in any jurisdiction. No securities of
ThromboGenics may be offered or sold within the United States without registration under
the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom,
and in accordance with any applicable U.S. state securities laws.

        For further information please contact:

        Wouter Piepers, Global Head of Corporate Communications
        +32-16-75-13-10 / +32-478-33-56-32

        Dr. Patrik De Haes, CEO

        Chris Buyse, CFO

        Citigate Dewe Rogerson
        David Dible/ Nina Enegren/ Sita Shah
        Tel: +44-20-7638-9571

        The Trout Group
        US Investor Relations
        Todd James/ Simon Harnest
        Tel: +1-646-378-2926

SOURCE ThromboGenics NV

Source: PR Newswire